Welcome
We manage the Government's investment in health research. Our vision is to improve the health and quality of life of all New Zealanders.
Funding Opportunities
The HRC allocates funding through an annual funding round for researcher initiated projects, Requests for Proposals, and a range of career development awards.
About Us
We invest in a broad range of research on issues important to New Zealand, and support the development of health research careers. Our mission is 'benefiting New Zealand through health research'.
News and Publications
We produce a wide range of publications and documents, which provide information about funding opportunities, research outcomes and HRC-related news.
Ethics and Regulatory
We help ensure all research involving human participants is based on good science, meets ethical standards and complies with best practice.
Contact Us
If you have any questions about the HRC or would like to know more about how our funding process works, please drop us a line.
Gene Technology Advisory Committee
Associate Professor Alan Davidson
Project
Associate Professor
Alan
Davidson
University of Auckland
Kidney organoids: Modelling kidney injury and preclinical drug testing
$1,182,356
36 months
Lay summary
Kidney disease is major health issue in New Zealand with an estimated 1:10 people having some degree of chronic kidney disease. The development of new therapies has been hampered by a lack of human cell-based models in the laboratory with which to test new drugs. We have overcome these barriers by developing a novel method to make human kidney organoids (mini kidneys grown in a petri dish) using stem cells. In addition, we have identified a class of compounds, PTBAs, that can reduce kidney injury and promote repair in animal models of kidney damage. In this proposal, we will combine these technologies by inducing kidney injury in the organoids and using this system to identify the most therapeutically active PTBA variant. These preclinical experiments will lay the groundwork for initiating human clinical trials with PTBAs in the future.
Print